Sign Up for Our Latest News
Stay informed with the latest updates, events, and breakthroughs from HKUST.
Anticancer prodrugs have attracted significant attention from the medical and scientific communities in recent years due to their potential to improve treatment precision while reducing adverse side effects. These drugs are specially engineered to remain inactive until they are activated at specific sites or under particular physiological conditions within the body, at which point they release their therapeutic effect.
The Hong Kong University of Science and Technology (HKUST) has achieved notable achievements in the Research Grants Council's (RGC) Senior Research Fellow Scheme (SRFS) and Research Fellow Scheme (RFS) for the 2026/27 exercise, with three distinguished scholars receiving the fellowship awards.